Allopurinol and Progression of CKD and Cardiovascular Events: Long-term Follow-up of a Randomized Clinical Trial

Background Asymptomatic hyperuricemia increases renal and cardiovascular (CV) risk. We previously conducted a 2-year, single-blind, randomized, controlled trial of allopurinol treatment that showed improved estimated glomerular filtration rate and reduced CV risk. Study Design Post hoc analysis of a...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	American journal of kidney diseases 2015-04, Vol.65 (4), p.543-549
Hauptverfasser:	Goicoechea, Marian, MD, PhD, Garcia de Vinuesa, Soledad, MD, Verdalles, Ursula, MD, Verde, Eduardo, MD, Macias, Nicolas, MD, Santos, Alba, MD, Pérez de Jose, Ana, MD, PhD, Cedeño, Santiago, MD, Linares, Tania, MD, Luño, Jose, MD, PhD
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Aged, 80 and over Allopurinol - pharmacology Allopurinol - therapeutic use allopurinol treatment cardiovascular (CV) risk Cardiovascular Diseases - epidemiology Chronic kidney disease (CKD) progression Creatinine - blood Disease Progression Female Follow-Up Studies Glomerular Filtration Rate - drug effects Gout Suppressants - pharmacology Gout Suppressants - therapeutic use Humans hyperuricemia Incidence Longitudinal Studies Male Middle Aged Nephrology renal disease Renal Insufficiency, Chronic - drug therapy Renal Insufficiency, Chronic - mortality Risk Factors Treatment Outcome Uric Acid - blood uric acid concentration
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!